Lycia files for a $100M IPO to take its LYTAC degraders into allergy
- Lycia Therapeutics filed publicly for an IPO of up to $100M on Nasdaq under LYCA, after a confidential filing in July.
- Its LYTAC platform, from Carolyn Bertozzi's lab, shuttles extracellular proteins to the lysosome for degradation.
- Lead LCA-0061 degrades IgE for food allergy and is in Phase 1; LCA-0321 targets Graves' disease autoantibodies.
💡 Points
Early healthy-volunteer data showing a deep IgE drop give the story a clinical anchor, and an IPO is a useful test of public-market appetite for degraders outside oncology. The competition is formidable, though: omalizumab and its successors already own IgE, so Lycia must show a durable, differentiated edge.
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms ↗